Sumit K. Subudhi

Jul 16, 2024 | nature.com | Andrew Hahn |Rebecca S. Tidwell |Amado J. Zurita |Sumit K. Subudhi |Pavlos Msaouel |Efstratios Koutroumpakis | +2 more

AbstractAndrogen signaling is central to prostate cancer and men’s health. Prior data indicates that increasing body fat is unfavorable in the localized setting yet associated with favorable outcomes in men with metastatic disease. Understanding the biological links between adiposity and prostate cancer may optimize the therapeutic index with ASI.

Aug 29, 2023 | onclive.com | Rana R. McKay |Arash Rezazadeh Kalebasty |Sumit K. Subudhi |Scott T. Tagawa |Ulka Vaishampayan

CAR T-Cell Therapy in Metastatic CRPC and Future Directions in CareClosing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.

Aug 29, 2023 | onclive.com | Rana R. McKay |Arash Rezazadeh Kalebasty |Sumit K. Subudhi |Scott T. Tagawa |Ulka Vaishampayan

Novel ADCs Must Keep Up With Moving Targets in Metastatic Breast CancerDr Massarelli on Addressing Unmet Needs in SCLCNK T-Cell Agonist Under Investigation in Combination With Pembrolizumab in Melanoma and NSCLC

Aug 15, 2023 | onclive.com | Rana R. McKay |Arash Rezazadeh Kalebasty |Sumit K. Subudhi |Scott T. Tagawa |Ulka Vaishampayan

Key opinion leaders share insight to novel combination strategies and clinical trials focused on radioligand therapy in metastatic castration-resistant prostate cancer.

Aug 15, 2023 | onclive.com | Rana R. McKay |Arash Rezazadeh Kalebasty |Sumit K. Subudhi |Scott T. Tagawa |Ulka Vaishampayan

Radioligands in the Treatment of Metastatic CRPC: Radium-223Continuing their segment on radioligand therapy in metastatic castration-resistant prostate cancer, panelists highlight data behind use of radium-223.